دورية أكاديمية
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
| العنوان: | Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort. |
|---|---|
| المؤلفون: | Álvarez H; Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coruña, Spain.; Universidade de Vigo, Vigo, Spain., Rava M; AIDS Research Network Cohort (CoRIS), National Center of Epidemiology (CNE), Health Institute Carlos III (ISCIII), Madrid, Spain., Martínez C; Methodology and Statistics Unit, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain., Portilla J; Hospital General Universitario de Alicante, Alicante, Spain., Peraire J; Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain., Rivero A; Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.; CIBERINFEC, Madrid, Spain., Cervero M; Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain., Mariño A; Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coruña, Spain., Poveda E; Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain., Llibre JM; Infectious Diseases and 'Fight AIDS and Infectious Diseases' Foundation, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. |
| مؤلفون مشاركون: | CoRIS Study Group |
| المصدر: | HIV medicine [HIV Med] 2022 Sep; Vol. 23 (8), pp. 825-836. Date of Electronic Publication: 2022 Mar 01. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley Original Publication: Oxford : Blackwell Science, c1999- |
| مواضيع طبية MeSH: | Anti-HIV Agents*/therapeutic use , HIV Infections*/drug therapy , HIV Integrase Inhibitors*/therapeutic use , HIV-1*, Adult ; Anti-Retroviral Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Humans ; Integrase Inhibitors/therapeutic use ; RNA/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load ; Viremia/drug therapy |
| مستخلص: | Objectives: To pinpoint factors associated with low-level viraemia (LLV) and virological failure (VF) in people living with HIV in the era of high-efficacy antiretroviral treatment (ART) and widespread use of integrase strand transfer inhibitor (INSTIs)-based ART. Methods: We included adults aged > 18 years starting their first ART between 2015 and 2018 in the Spanish HIV/AIDS Research Network National Cohort (CoRIS). Low-level viraemia was defined as plasma viral load (pVL) of 50-199 copies/mL at weeks 48 and 72 and VF was defined as pVL ≥ 50 copies/mL at week 48 and pVL ≥ 200 copies/mL at week 72. Multivariable logistic regression models assessed the impact on LLV and VF of baseline CD4 T-cell count, CD4/CD8 T-cell ratio and pVL, initial ART classes, age at ART initiation, time between HIV diagnosis and ART initiation, gender and transmission route. Results: Out of 4186 participants, 3120 (76.0%) started INSTIs, 455 (11.1%) started boosted protease inhibitors (bPIs) and 443 (10.8%) started nonnucleoside reverse transcriptase inhibitors (NNRTIs), either of them with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Low-level viraemia was met in 2.5% of participants and VF in 4.3%. There were no significant differences throughout the years for both virological outcomes. Baseline HIV-1 RNA > 5 log Conclusions: The rates of LLV and VF were low but remained steady throughout the years. Baseline HIV-1 RNA > 5 log (© 2022 British HIV Association.) |
| References: | Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among participants with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853-860. Castro P, Plana M, González R, et al. Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected participants. AIDS Res Hum Retroviruses. 2013;29(1):68-76. Hattab S, Guihot A, Guiguet M, et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis. 2014;14:122. Baker JV, Sharma S, Grund B, et al. Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis. 2017;4(4):ofx262. Elvstam O, Medstrand P, Jansson M, et al. Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease? HIV Med. 2019;20(9):571-580. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA. 1999;96(20):10958-10961. Passaes CP, Sáez-Cirión A. HIV cure research: advances and prospects. Virology. 2014;454-455:340-352. Cillo AR, Mellors JW. Which therapeutic strategy will achieve a cure for HIV-1? Curr Opin Virol. 2016;18:14-19. Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected participants experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204(4):515-520. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230-1238. Laprise C, de Pokomandy A, Baril JG, et al. Virologic failure following persistent low-level viremia in a cohort of HIV-positive participants: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489-1496. Swenson LC, Min JE, Woods CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014;28(8):1125-1134. Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165-1173. Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected participants experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir Ther. 2015;20(6):655-660. Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected participants. AIDS. 2015;29(3):373-383. Elvstam O, Medstrand P, Yilmaz A, et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One. 2017;12(7):e0180761. Bernal E, Gómez JM, Jarrín I, et al. Low-level viremia is associated with clinical progression in HIV-infected participants receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2018;78(3):329-337. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188-197. Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145-2152. Fleming J, Mathews WC, Rutstein RM, et al. Low level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019;33(13):2005-2012. Esber A, Polyak C, Kiweewa F, et al. Persistent low-level viremia predicts subsequent virologic failure: is it time to change the third 90? Clin Infect Dis. 2019;69(5):805-812. Zhang T, Ding H, An M, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis. 2020;20(1):147. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, et al. Grupo de trabajo de la Cohorte de la Red de Investigación en Sida (CoRIS) [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin. 2007;25(1):23-31. Lalama CM, Jennings C, Johnson VA, et al. Comparison of three different FDA-approved plasma HIV-1 RNA assay platforms confirms the virologic failure endpoint of 200 copies per milliliter despite improved assay sensitivity. J Clin Microbiol. 2015;53(8):2659-2666. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72(1):58-64. Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/ emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34(5):707-718. Chun T-W, Justement JS, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis. 2002;185(11):1672-1676. Sharma S, Schlusser KE, de la Torre P, et al. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. AIDS. 2019;33(8):1335-1344. The Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. BMC Infect Dis. 2020;20:728. Pernas B, Grandal M, Mena A, et al. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS. 2014;28(12):1837-1840. Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, et al. Initial treatment response among HIV subtype F infected participants who started antiretroviral therapy based on integrase inhibitors. AIDS. 2018;32(1):121-125. |
| فهرسة مساهمة: | Investigator: S Moreno; D Dalmau; ML Navarro; MI González; F García; JA Iribarren; F Gutiérrez; R Rubio; F Vidal; J Berenguer; J González; MÁ Muñoz-Fernández; I Jarrín; B Alejos; C Moreno; C Iniesta; LM García Sousa; N Sanz Pérez; MÁ Muñoz-Fernández; I Consuegra Fernández; E Merino; G García; I Portilla; I Agea; J Sánchez-Payá; JC Rodríguez; L Gimeno; L Giner; M Díez; M Carreres; S Reus; V Boix; D Torrús; A López Lirola; D García; F Díaz-Flores; JL Gómez; MDM Alonso; R Pelazas; J Hernández; MR Alemán; MI Hernández; V Asensi; E Valle; ME Rivas Carmenado; T Suárez-Zarracina Secades; L Pérez Is; R Rubio; F Pulido; O Bisbal; A Hernando; L Domínguez; D Rial Crestelo; L Bermejo; M Santacreu; JA Iribarren; J Arrizabalaga; MJ Aramburu; X Camino; F Rodríguez-Arrondo; MÁ von Wichmann; L Pascual Tomé; MÁ Goenaga; MJ Bustinduy; H Azkune; M Ibarguren; A Lizardi; X Kortajarena; MP Carmona Oyaga; M Umerez Igartua; F Gutiérrez; M Masiá; S Padilla; C Robledano; JG Colomé; A Adsuar; R Pascual; M Fernández; JA García; X Barber; V Agullo Re; J García Abellán; R Pascual Pérez; M Roca; R Muga; A Sanvisens; D Fuster; J Berenguer; JC López Bernaldo de Quirós; I Gutiérrez; M Ramírez; B Padilla; P Gijón; T Aldamiz-Echevarría; F Tejerina; FJ Parras; P Balsalobre; C Diez; L Pérez Latorre; C Fanciulli; F Vidal; C Viladés; S Veloso; M Vargas; M Olona; A Rull; E Rodríguez-Gallego; V Alba; AJ Castellanos; M López-Dupla; M Montero Alonso; J López Aldeguer; M Blanes Juliá; M Tasias Pitarch; I Castro Hernández; E Calabuig Muñoz; S Cuéllar Tovar; M Salavert Lletí; J Fernández Navarro; J González-García; F Arnalich; JR Arribas; JI Bernardino de la Serna; JM Castro; A Delgado Hierro; L Escosa; P Herranz; V Hontañón; S García-Bujalance; M García López-Hortelano; A González-Baeza; ML Martín-Carbonero; M Mayoral; MJ Mellado; R Esteban Micán; R Montejano; ML Montes; V Moreno; I Pérez-Valero; G Rúa Cebrián; B Rodés; T Sainz; E Sendagorta; N Stella Alcáriz; E Valencia; JR Blanco; JA Oteo; V Ibarra; L Metola; M Sanz; L Pérez-Martínez; P Arazo; G Sampériz; D Dalmau; A Jaén; M Sanmartí; M Cairó; J Martinez-Lacasa; P Velli; R Font; M Martínez; F Aiello; M Rivero Marcotegui; J Repáraz; M Gracia Ruiz de Alda; MT de León Cano; B Pierola Ruíz de Galarreta; MJ Amengual; G Navarro; M Cervantes García; S Calzado Isbert; M Navarro Vilasaro; I de Los Santos; J Sanz Sanz; A Salas Aparicio; C Sarria Cepeda; L García-Fraile Fraile; E Martín Gayo; JL Casado Osorio; F Dronda Núñez; A Moreno Zamora; MJ Pérez Elías; C Gutiérrez; N Madrid; S Del Campo Terrón; S Serrano Villar; MJ Vivancos Gallego; J Martínez Sanz; U Anxa Urroz; T Velasco; E Bernal; A Cano Sánchez; A Alcaraz García; J Bravo Urbieta; Á Muñoz Pérez; MJ Alcaraz; MDC Villalba; J Hernández Quero; L Muñoz Medina; M Álvarez; N Chueca; D Vinuesa García; C Martínez-Montes; C Guerrero Beltrán; A de Salazar González; A Fuentes López; J Del Romero; M Raposo Utrilla; C Rodríguez; T Puerta; JC Carrió; M Vera; J Ballesteros; O Ayerdi; A Antela; E Losada; M Riera; M Peñaranda; MA Ribas; AA Campins; C Vidal; F Fanjul; J Murillas; F Homar; HH Vilchez; ML Martin; A Payeras; J Santos; C Gómez Ayerbe; I Viciana; R Palacios; C Pérez López; CM Gonzalez-Domenec; P Viciana; N Espinosa; LF López-Cortés; D Podzamczer; A Imaz; J Tiraboschi; A Silva; M Saumoy; P Prieto; E Ribera; A Currán; J Olalla Sierra; J Pérez Stachowski; A Del Arco; J de la Torre; JL Prada; JM García de Lomas Guerrero; OJ Martínez; FJ Vera; L Martínez; J García; B Alcaraz; A Jimeno; Á Castro Iglesias; B Pernas Souto; Á Mena de Cea; J Muñoz; M Zuriñe Zubero; JM Baraia-Etxaburu; S Ibarra Ugarte; OL Ferrero Beneitez; J López de Munain; MM Cámara López; M de la Peña; M Lopez; I López Azkarreta; C Galera; H Albendin; A Pérez; A Iborra; A Moreno; MA Merlos; A Vidal; M Meca; C Amador; F Pasquau; J Ena; C Benito; V Fenoll; C Gil Anguita; JT Algado Rabasa; I Suárez-García; E Malmierca; P González-Ruano; D Martín Rodrigo; MP Ruíz Seco; MO Mohamed-Balghata; MA Gómez Vidal; MA de Zarraga; V Estrada Pérez; MJ Téllez Molina; J Vergas García; J Pérez-Somarriba Moreno; M Górgolas; A Cabello; B Álvarez; L Prieto; J Sanz Moreno; A Arranz Caso; C Hernández Gutiérrez; M Novella Mena; MJ Galindo Puerto; RF Vilalta; A Ferrer Ribera; A Rivero Juárez; P López López; I Machuca Sánchez; M Frias Casas; Á Camacho Espejo; R Torres Perea; JA Pineda; P Rincón Mayo; J Macías Sánchez; N Merchante Gutiérrez; LM Real; A Corma Gómez; M Fernández Fuertes; A González-Serna; A Pérez; M Crespo; L Morano; C Miralles; A Ocampo; G Pousada Keywords: HIV-1; antiretroviral treatment-naïve; integrase inhibitors; low-level viraemia; virological failure |
| المشرفين على المادة: | 0 (Anti-HIV Agents) 0 (Anti-Retroviral Agents) 0 (HIV Integrase Inhibitors) 0 (Integrase Inhibitors) 0 (Reverse Transcriptase Inhibitors) 63231-63-0 (RNA) |
| تواريخ الأحداث: | Date Created: 20220302 Date Completed: 20220815 Latest Revision: 20220908 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/hiv.13265 |
| PMID: | 35234328 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1468-1293 |
|---|---|
| DOI: | 10.1111/hiv.13265 |